Innovating Works

CUCUMBER

Financiado
Bringing to market the world s first integrated medical cooling system for minim...
Bringing to market the world s first integrated medical cooling system for minimizing brain damage in stroke patients. Stroke-related disabilities remains a major challenge faced by patients, their families and healthcare systems worldwide and is estimated to cost healthcare systems over €45B/year. In Europe, there are over 1.1M new incidences of... Stroke-related disabilities remains a major challenge faced by patients, their families and healthcare systems worldwide and is estimated to cost healthcare systems over €45B/year. In Europe, there are over 1.1M new incidences of stroke per year, a third of which will result in permanent disabilities such as limited mobility and affected cognitive function. These handicaps are a result of the brain damage caused by blocked blood flow to the brain, as well as further damage following the recanalization of an arterial blockage. Targeted temperature management (TTM), also known as 'brain cooling', is a method that has proven effective in reducing brain injury in sudden cardiac arrest patients. Extrapolation of TTM to stroke will have a tremendous impact on patient outcomes, however, the limited functionalities of current cooling technologies prevent this realization. The CUCUMBER consortium, whose expertise range from engineering, manufacturing, clinical neurology and stroke, are working to change this paradigm by developing CoolConnect, the world's first cooling device that accommodates the needs of stroke treatment to improve patient’s outcome, survival, and neurological outcome. CoolConnect is an integrated device composed of 3 components (RhinoChill, BrainCool, and BrainTemp sensor), which come together to address the 3 critical phases of brain cooling, 1)Early cooling, 2)Cooling during reperfusion and 3)maintenance cooling. CoolConnect is the only solution in development designed for this purpose. FTI grant is requested to fast-track the market launch of CoolConnect by 2024, to ensure broad and sustainable uptake in the following years. Our main aim is to validate CoolConnect in a large, multicenter trial, and to implement all market access and communication activities critical for broad market adoption. There are >288,000 eligible patients for CoolCoonect per year in EU/US, and yearly revenues of €56M can be anticipated following 5 years of commercialization. ver más
31/05/2025
UKLFR
4M€
Duración del proyecto: 54 meses Fecha Inicio: 2020-11-09
Fecha Fin: 2025-05-31

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2020-11-09
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-FTI-2018-2020: Fast Track to Innovation (FTI)
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 4M€
Líder del proyecto
UNIVERSITAETSKLINIKUM FREIBURG No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5